BioLife Solutions (BLFS) Stock Price, News & Analysis

Company Overview

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies. In addition to its core media and instrumentation, BioLife provides technical support, training and validation services to help customers integrate its products into regulated processes and meet GMP-compliance requirements.

Headquartered in Bothell, Washington, BioLife Solutions serves a global customer base spanning academic research centers, contract development and manufacturing organizations (CDMOs) and commercial biopharmaceutical companies. The company has established distribution channels in North America, Europe and Asia to support the growing demand for standardized, clinical-grade preservation solutions. BioLife’s management team is led by President and Chief Executive Officer Warren T. Thompson, whose experience in the life sciences industry has guided strategic product development and expansion initiatives. Through continuous innovation in biopreservation technologies, BioLife Solutions aims to enable the safe and reliable delivery of next-generation cell therapies worldwide.

Key Stats

• Today's Range: $34.12 to $34.76
• 50-Day Range: $24.88 to $34.66
• 52-Week Range: $17.86 to $34.76
• Volume: 655,841 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $1.69 billion
• P/E Ratio: 29.88
• Dividend Yield: N/A
• Price Target: $31.38
• Consensus Rating: Hold

BioLife Solutions Stock Analysis - MarketRank™

BioLife Solutions scored higher than 66% of companies evaluated by MarketBeat, and ranked 253rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

BioLife Solutions has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 strong buy rating, 1 buy rating, 7 hold ratings, and 1 sell rating.

Downside Risk

BioLife Solutions has a consensus price target of $31.38, representing about 9.5% downside from its current price of $34.66.

Amount of Analyst Coverage

BioLife Solutions has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 433.33%

Earnings Growth

Earnings for BioLife Solutions are expected to grow by 433.33% in the coming year, from $0.03 to $0.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLife Solutions is 29.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLife Solutions is 29.88, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.66.

Price to Book Value per Share Ratio

BioLife Solutions has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.98% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 4.97.

Change versus previous month

Short interest in BioLife Solutions has recently decreased by 5.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLife Solutions does not currently pay a dividend.

Dividend Growth

BioLife Solutions does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.33

News Sentiment

BioLife Solutions has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BioLife Solutions this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for BLFS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,125,000.00 in company stock.

Percentage Held by Insiders

2.20% of the stock of BioLife Solutions is held by insiders.

Percentage Held by Institutions

93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:BLFS
• CIK: 834365
• Web: www.biolifesolutions.com
• Phone: (425) 402-1400
• Fax: 425-402-1433
• Employees: 440
• Year Founded: 1987

Price Target and Rating

• Average Price Target for BioLife Solutions: $31.38
• High Price Target: $34.00
• Low Price Target: $31.00
• Potential Upside/Downside: -9.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: 29.88
• Forward P/E Ratio: 1,155.33
• P/E Growth: N/A
• Net Income: -$4.59 million
• Net Margins: 53.29%
• Pretax Margin: -10.51%
• Return on Equity: 2.80%
• Return on Assets: 2.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.30
• Quick Ratio: 5.50

Sales & Book Value

• Annual Sales: $96.21 million
• Price / Sales: 17.60
• Cash Flow: $0.23 per share
• Price / Cash Flow: 148.18
• Book Value: $7.72 per share
• Price / Book: 4.49

Miscellaneous

• Outstanding Shares: 48,860,000
• Free Float: 47,782,000
• Market Cap: $1.69 billion
• Optionable: Optionable
• Beta: 1.93